Xeljanz, Rinvoq, and Olumiant Lawsuits for Heart Attacks, Strokes, Cancers, Deaths
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Xeljanz (tofacitinib), Rinvoq (upadacitinib), and Olumiant (baricitinib) are three Janus kinase (JAK) inhibitors approved by the FDA for treatment of rheumatoid arthritis as well as other medical conditions. Xeljanz is a Pfizer drug, Rinvoq is an AbbVie drug, and Olumiant is an Eli Lilly drug.
In December 2021 these drug companies revised the “Black-Box” warnings for Xeljanz, Rinvoq, and Olumiant to include more information about the increased risk of various adverse drug reactions, including serious heart-related events, cancer, blood clots, and death.
Our law firm is investigating possible drug injury lawsuits for patients who used Xeljanz, Rinvoq, or Olumiant and then suffered one of the serious side effects associated with these JAK inhibitors drugs. In particular, heart problems such as heart attacks, strokes, pulmonary embolism (PE), and deep vein thrombosis (DVT), as well as cancers such as lymphoma and lung cancer.
According to the FDA, some of the serious side effects and adverse drug events related to Xeljanz, Rinvoq, and Olumiant are:
- Heart Attacks
- Myocardial Infarction (MI)
- Strokes — Ischemic / due to a blood clot
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Arterial Thrombosis
- Lymphoma
- Lung Cancer
- Other Cancers
- Death
As stated above, our law firm is investigating possible Xeljanz, Rinvoq, and Olumiant lawsuits for patients who have suffered serious side effects or adverse drug reactions. We would like to help you or someone you know with a Xeljanz, Rinvoq, or Olumiant drug injury case. Please feel free to contact us, at your convenience.
Free Xeljanz, Rinvoq, and Olumiant Case Evaluation
We encourage you to submit a Xeljanz, Rinvoq, and Olumiant Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about your possible Xeljanz lawsuit. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Xeljanz, Rinvoq, and Olumiant
This excerpt from the “Advisory – Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer” issued in January 2022 provides an overview of the Xeljanz drug safety issue, and how the Xeljanz side effects risks may also apply to Olumiant and Rinvoq:
Health Canada completed a safety review that confirmed a link between the use of Xeljanz/Xeljanz XR and the increased risks of serious heart-related problems and cancer, especially in older patients, patients who are current or past smokers, and patients with cardiovascular or cancer risk factors. Health Canada’s review also found that all patients treated with Xeljanz 10 mg twice daily had a higher risk of death, blood clots and serious infections, compared to patients treated with Xeljanz 5 mg twice daily or tumour necrosis factor inhibitors (TNFi)….
Health Canada has also initiated a new safety review of the potential risks of serious heart-related problems, cancer and blood clots with two other drugs of the same class as Xeljanz/Xeljanz XR (i.e. Olumiant and Rinvoq) that work similarly for the treatment of similar diseases.
To read more of this article, click below:
The Health Canada Xeljanz Advisory gives some more detailed information in a section intended for healthcare professionals but, no doubt, of interest to patients using Xeljanz — as well as Olumiant or Rinvoq, perhaps:
- Inform patients that Xeljanz/Xeljanz XR may increase their risk of major adverse cardiovascular events including non-fatal myocardial infarction. Instruct all patients, especially geriatric patients, current or past smokers, or patients with other cardiovascular risk factors, to be alert for signs and symptoms of cardiovascular events.
- Inform patients that Xeljanz/Xeljanz XR may increase their risk of certain cancers, and that lung cancer, lymphoma and other cancers have been observed in patients taking Xeljanz. Instruct patients to inform their healthcare provider if they have ever had any type of cancer.
Our law firm is investigating possible drug injury lawsuits for patients who used Xeljanz, Olumiant, or Rinvoq and then suffered one of the serious side effects associated with these JAK inhibitors drugs. In particular, heart problems such as heart attacks, strokes, pulmonary embolism (PE), and deep vein thrombosis (DVT), as well as cancers such as lymphoma and lung cancer.
[Read article in full at original source]Earlier articles about Xeljanz, Rinvoq, and Olumiant by attorney Tom Lamb on the Side Effects Blog:
- Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq
- Olumiant and Those JAK Inhibitors Drug Safety Issues: Eli Lilly’s “Spin”
- Drug Regulator MHRA Imposes More Xeljanz Use Limitations in October 2021
- Possible New Xeljanz Side Effect: Peripheral Neuropathy
- Xeljanz: Heart Attacks, Strokes, Cancers, Blood Clots, and Deaths – Updated FDA Warnings 2021
- FDA Advisory Committee Meeting Could Review Risk/Benefit Profiles for All JAK Inhibitors
- Possible FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq in Future
- Are Heart Problems and Cancers JAK Inhibitors Drug Class Safety Issues?
- New Xeljanz Warnings From FDA in 2021; Are Other JAK Inhibitors Next?
- Xeljanz 2021 FDA Warnings: Xeljanz Causing Heart Problems and Xeljanz Causing Cancer
- Xeljanz Side Effects Include Blood Clots, Pulmonary Embolism, And Serious Infections
- Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots
- Xeljanz FDA Drug Safety Communication About Increased Risks of Blood Clots And Death
- Serious Side Effects For Xeljanz 10 mg Dose Leads To European Drug Safety Regulatory Action
- Xeljanz Used For Ulcerative Colitis May Increase Risk Of Pulmonary Embolism
More articles about Xeljanz, Rinvoq, and Olumiant on our Drug Safety Developments website:
- Black Box Warning Label Added to JAK Inhibitors Including Xeljanz, Rinvoq and Olumiant
- Health Canada Issues Safety Review for Xeljanz in April 2021
- Xeljanz Safety Trial Results Which May Lead to Xeljanz Recall
- Will There Be a Xeljanz Recall in the Future?